Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fifteen Korean Drug Firms Granted Innovative Status Charged With Unfair Trade Practices

This article was originally published in PharmAsia News

Executive Summary

Old habits seem to die hard as 15 Korean pharma companies among 43 granted tax breaks and financial incentives to compete at home and abroad are charged with unfair trade practices, including making rebate payments to secure orders.

You may also be interested in...



South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment

SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.

Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose

Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC079565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel